Share on StockTwits

Delcath Systems (NASDAQ:DCTH) was the recipient of a significant decline in short interest in May. As of May 30th, there was short interest totalling 418,239 shares, a decline of 19.8% from the May 15th total of 521,616 shares, AnalystRatingsNetwork.com reports. Currently, 4.5% of the shares of the stock are short sold. Based on an average trading volume of 218,756 shares, the days-to-cover ratio is currently 1.9 days.

Several analysts have recently commented on the stock. Analysts at Zacks downgraded shares of Delcath Systems from an “outperform” rating to a “neutral” rating in a research note on Tuesday, May 13th. They now have a $3.70 price target on the stock.

Delcath Systems (NASDAQ:DCTH) opened at 2.78 on Friday. Delcath Systems has a 52-week low of $2.44 and a 52-week high of $10.56. The stock’s 50-day moving average is $2.82 and its 200-day moving average is $4.20. The company’s market cap is $26.2 million.

Delcath Systems (NASDAQ:DCTH) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.57) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.64) by $0.07. The company had revenue of $0.31 million for the quarter, compared to the consensus estimate of $0.20 million. Delcath Systems’s revenue was down 18.4% compared to the same quarter last year. Analysts expect that Delcath Systems will post $-2.22 EPS for the current fiscal year.

Delcath Systems, Inc (NASDAQ:DCTH) is a development-stage company that has developed a system designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.